Desk›Healthcare› Gland Pharma Ltd
Gland Pharma Ltd
BSE 543245 · NSE GLAND · ISIN INE068V01023 · Group A · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹2,886.05
+0.46%
BSE close, 28 August 2026
₹47,610.20 cr
16.5 cr shares · Mid cap
₹22,933.55 cr
as published
34.1× · 5.19×
EPS ₹84.55 · BV ₹556.08
4,552.09 / 1,299.55
₹ cr, as filed
40
12 selected · 30%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -5.0% |
|---|---|
| Against 52-week low | +83.2% |
| Day change | +0.46% |
| Size band | Mid cap |
| Index membership | NIFTY 500 |
Valuation as published by BSE
| Earnings per share | ₹84.55 |
|---|---|
| Price / earnings | 34.13× |
| Price / book | 5.19× |
| Book value — derived, price ÷ P/B | ₹556.08 |
| Return on equity | 15.20% |
| Operating margin | 41.37% |
| Net margin | 28.32% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 15.21%
- ROE as published
- 15.20%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 1,286.64 | 364.39 | 22.11 | 41.37% | 28.32% |
| Mar-26 · Q | 1,261.59 | 420.45 | 25.52 | 48.67% | 33.33% |
| FY25-26 | 4,552.09 | 1,299.55 | 78.88 | 42.68% | 28.55% |
Quarter on quarter
- Revenue, quarter on quarter
- +2.0%
- Net profit, quarter on quarter
- -13.3%
- Operating margin, quarter on quarter
- -730 bps
Disclosure profile 40 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Press Release | 3 |
| Change in Directorate | 2 |
| Acquisition | 1 |
| Board Outcome | 1 |
| Change in Management | 1 |
| Concall Transcript | 1 |
| Fundraising | 1 |
| Investor Presentation | 1 |
| Results | 1 |
| Selected sub-total | 12 |
| Procedural | |
| Analyst / Investor Meet | 7 |
| Newspaper Publication | 4 |
| AGM / EGM | 3 |
| Postal Ballot | 3 |
| SAST | 3 |
| General | 2 |
| Annual Report | 1 |
| BRSR | 1 |
| Board Meeting | 1 |
| ESOP Allotment | 1 |
| Outcome | 1 |
| Trading Window | 1 |
| Procedural sub-total | 28 |
| Total | 40 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
40 filings · 12 selected · busiest 2026-08-10
Filing rhythm · the twelve most recent
2026-09-082026-10-07
SelectedProcedural
Filings
40 in the window · 15 earlier on record
-
7 October 2026 ·
Newspaper Publication
Newspaper Publication regarding the dipatch of Notice of Postal Ballot
Company Update / Newspaper Publication View filing →
-
6 October 2026 ·
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Postal Ballot Notice
AGM/EGM / Postal Ballot View filing →
-
1 October 2026 ·
Change in Directorate
Resignation of Mr. Wenjie Zhang as a Non-Executive & Non-Independent Director and Appointment of Mr. Xingli Wang as an Additional Director (Non-Executive and Non-Independent Director)
Company Update / Change in Directorate View filing →
-
1 October 2026 ·
Updates on Acquisition
Investment by Gland Pharma Limited in Gland Pharma USA Inc. and Investment by Gland Pharma USA Inc. into Novelstar Pharma Inc.
Company Update / Acquisition View filing →
-
1 October 2026 ·
Board Meeting Outcome for Outcome Of Board Meeting - 01-10-2026
Outcome of Board Meeting held on October 01, 2026
Others / Outcome without intimation View filing →
-
1 October 2026 ·
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Fosun Pharma Industrial Pte Ltd
Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
-
30 September 2026 ·
Closure of Trading Window
Closure of Trading Window
Insider Trading / SAST / Closure of Trading Window View filing →
-
30 September 2026 ·
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mirae Asset Mutual Fund
Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
-
29 September 2026 ·
Newspaper Publication
Copy of Newspaper Publication
Company Update / Newspaper Publication View filing →
-
10 September 2026 ·
Analyst / Investor Meet - Intimation
Schedule of Investor Meetings
Company Update / Analyst / Investor Meet View filing →
-
8 September 2026 ·
Analyst / Investor Meet - Intimation
Investor Meet Intimation
Company Update / Analyst / Investor Meet View filing →
-
8 September 2026 ·
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Fosun Pharma Industrial Pte Ltd
Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
-
4 September 2026 ·
Analyst / Investor Meet - Intimation
Schedule of Investor Meet Intimation
Company Update / Analyst / Investor Meet View filing →
-
1 September 2026 ·
Conclusion Of USFDA Inspection At Company's Facilities Situated At Visakhapatnam
Conclusion of USFDA Inspection at Company's Facilities situated at Visakhapatnam
Company Update / General View filing →
-
31 August 2026 ·
Analyst / Investor Meet - Intimation
Schedule of Investor Meets
Company Update / Analyst / Investor Meet View filing →
-
26 August 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
48th AGM Voting Results along with Scrutinizers Report
AGM/EGM / AGM View filing →
-
25 August 2026 ·
-
17 August 2026 ·
Earnings Call Transcript
Q1FY27 Earnings Call Transcript
Company Update / Earnings Call Transcript View filing →
-
14 August 2026 ·
Change in Management
Appointment of Chief Executive Officer of the Company
Company Update / Change in Management View filing →
-
11 August 2026 ·
Newspaper Publication
Newspaper Publication on Q1FY27 Financial Results
Company Update / Newspaper Publication View filing →
-
10 August 2026 ·
Analyst / Investor Meet - Outcome
Q1FY27 Earnings Call Audio recording
Company Update / Analyst / Investor Meet View filing →
-
10 August 2026 ·
Analyst / Investor Meet - Intimation
Schedule of Investor Meets
Company Update / Analyst / Investor Meet View filing →
-
10 August 2026 ·
Investor Presentation
Investor Presentation on Q1FY27 Financial Results
Company Update / Investor Presentation View filing →
-
10 August 2026 ·
Press Release / Media Release
Press release on Q1FY27 Financial Results
Company Update / Press Release / Media Release View filing →
-
10 August 2026 ·
Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended June 30, 2026
Outcome of Board Meeting
Board Meeting / Outcome of Board Meeting View filing →
-
10 August 2026 ·
Unaudited Financial Results For The Quarter Ended June 30, 2026
Unaudited Financial results for the quarter ended June 30, 2026
Result / Financial Results View filing →
-
5 August 2026 ·
Press Release / Media Release
Gland Pharma announces strategic collaboration with Neuland Laboratories for sterile API Manufacturing
Company Update / Press Release / Media Release View filing →
-
31 July 2026 ·
Letter To Shareholders
Letter to Shareholders regarding dispatch of 48th AGM Notice and Annual report for the FY 2025-26
Company Update / General View filing →
-
31 July 2026 ·
Business Responsibility and Sustainability Reporting (BRSR)
BRSR Report for the year ended March 31, 2026
Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
-
31 July 2026 ·
Reg. 34 (1) Annual Report.
Annual Report for the FY 2025-26
Others / Reg. 34 (1) Annual Report View filing →
-
31 July 2026 ·
-
30 July 2026 ·
Allotment of ESOP / ESPS
Allotment of Equity Shares under ESOPS
Company Update / Allotment of ESOP / ESPS View filing →
-
30 July 2026 ·
Issue of Securities
Grant of Stock Options under Gland Pharma Employee Stock Option Scheme, 2025
Company Update / Issue of Securities View filing →
-
29 July 2026 ·
Press Release / Media Release
Gland Pharma receives approval for Suggamadex Injection
Company Update / Press Release / Media Release View filing →
-
28 July 2026 ·
Newspaper Publication
Copy of News Paper Publication
Company Update / Newspaper Publication View filing →
-
24 July 2026 ·
Analyst / Investor Meet - Intimation
Q1FY27 Earnings Call Intimation
Company Update / Analyst / Investor Meet View filing →
-
24 July 2026 ·
Board Meeting Intimation for Declaration Of Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30, 2026
Gland Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Unaudited Standalone and Consolidated ....
Board Meeting / Board Meeting View filing →
-
20 July 2026 ·
Change in Directorate
Reappointment of Mr. Vetter and Appointment of Mr. Keller as Independent Directors of the Company
Company Update / Change in Directorate View filing →
-
20 July 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Scrutinizers Report on the Postal Ballot
AGM/EGM / Postal Ballot View filing →
-
20 July 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Postal Ballot Outcome
AGM/EGM / Postal Ballot View filing →
RSS feed for Gland Pharma Ltd · the 50 most recent filings